Code

AZGS2025103

Naam

ATTAIN

Omschrijving

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants with Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Start inclusieperiode

1-8-2026

Coördinator

Mieke Vanhaverbeke

Telefoon

056633188

[email protected]

Algemeen

Contact